{"gene":"COL9A1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2007,"finding":"A COL9A1 enhancer element contains four SOX9 consensus binding sites arranged as two pairs of dimeric binding sites; mutation of any one of the four sites eliminates enhancer activity in chondrocytic cells, and increasing the spacing between the two pairs also eliminates activity, indicating that two SOX9 dimers must interact (directly or indirectly) when bound at the two pairs of sites to form a functional transcriptional activation complex.","method":"Enhancer reporter assays in chondrocytic cells and 10T1/2 cells, site-directed mutagenesis of individual SOX9 binding sites, SOX9 cotransfection/overexpression","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro/cell-based reconstitution with mutagenesis of all four sites plus spacing mutations, single lab but multiple orthogonal mutational approaches","pmids":["17264118"],"is_preprint":false},{"year":2020,"finding":"LSD1 (Lysine-Specific Demethylase-1) negatively regulates COL9A1 in human articular chondrocytes: LSD1 physically interacts with the transcription factor SOX9 and is recruited to the COL9A1 promoter, repressing its expression; LSD1 depletion prevents IL-1β-induced decrease in COL9A1 in OA chondrocytes.","method":"RNA sequencing after LSD1 loss-of-function, co-immunoprecipitation of LSD1 with SOX9, chromatin immunoprecipitation (ChIP) at COL9A1 promoter, siRNA knockdown in OA chondrocytes with IL-1β treatment","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, and functional rescue in a single study with multiple orthogonal methods","pmids":["32878268"],"is_preprint":false},{"year":1999,"finding":"A short transcriptional isoform of Col9a1 (generated by alternative transcription) is the exclusive isoform expressed in bone (osteoblasts/alveolar bone); Col9a1-null mutant mice show abnormal alveolar bone wound healing with absent or disorganized trabecular bone and abnormal type X collagen immunostaining in primary spongiosa, establishing that the short isoform supports bone restoration and remodeling.","method":"Sequence-specific PCR distinguishing long vs. short isoforms, immunolocalization of type IX collagen in healing bone, Col9a1-null mutant mouse analysis (histology, immunostaining for type X collagen)","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with specific skeletal phenotype plus isoform-specific PCR and immunolocalization, single lab with multiple methods","pmids":["10595929"],"is_preprint":false},{"year":2008,"finding":"Short collagen IX (encoded by the col9a1 gene via alternative transcription) is expressed by osteoblasts and incorporated into mineralized bone matrix; col9a1 heterozygous and null mutant mice exhibit trabecular bone loss associated with enlarged, flattened osteoclasts that form large resorption pits on collagen IX-deficient bone surfaces lacking normal nanotopography; col9a1(+/-) osteoblasts show elevated RANKL/osteoprotegerin ratio, suggesting a non-cell-autonomous mechanism by which bone matrix collagen IX limits osteoclastic resorption.","method":"microCT and non-decalcified histology of col9a1-null and heterozygous mice, gene expression assays (PCR, microarray), TRACP-5b and CTX serum assays, in vitro osteoclast culture on mutant vs. wild-type calvaria, RAW264.7-derived osteoclast morphology assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO/heterozygote model with multiple orthogonal in vivo and in vitro readouts in single lab","pmids":["18251701"],"is_preprint":false},{"year":2008,"finding":"Collagen type IX (including the COL9A1-encoded α1 chain) localizes within the tectorial membrane and in fibrocytes of the spiral ligament of the cochlea, as demonstrated by immunogold cytochemistry at the ultrastructural level.","method":"Confocal immunocytochemistry and postembedding immunogold electron microscopy on rat and mouse cochlear cryostat sections","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct ultrastructural localization in cochlea, single lab, single method","pmids":["18448257"],"is_preprint":false},{"year":2017,"finding":"In antler chondrocytes, ATRA signaling induces COL9A1 expression via a BMP2-WNT4-RUNX1 pathway: RARα mediates the effect (RARα agonist Am80 induces COL9A1; RARα antagonist blocks it); CRABP2 is required for ATRA-induced COL9A1 upregulation; BMP2 and WNT4 act sequentially (WNT4 downstream of BMP2) to mediate ATRA's effect; RUNX1 acts downstream of BMP2 and WNT4 as a transcriptional intermediary to activate COL9A1.","method":"siRNA knockdown and overexpression of CRABP2, RARα, RXRα, BMP2, WNT4, RUNX1 in antler chondrocytes; pharmacological agonist/antagonist treatments; RT-PCR/Western blot for COL9A1","journal":"Journal of experimental zoology. Part B, Molecular and developmental evolution","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — epistasis established by sequential knockdown/overexpression experiments, single lab, multiple pathway components tested","pmids":["28643469"],"is_preprint":false},{"year":2001,"finding":"A mutation in COL9A1 (in the alpha1(IX) chain) can cause autosomal dominant multiple epiphyseal dysplasia (MED), establishing COL9A1 as a causative gene for MED and expanding locus heterogeneity for this condition.","method":"Mutation screening of COL9A1 coding region by SSCP/sequencing in MED probands; linkage analysis to exclude other known loci","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — disease-causing mutation identified by sequencing in a single family, no functional reconstitution","pmids":["11565064"],"is_preprint":false},{"year":2006,"finding":"Homozygous loss-of-function mutation (R295X) in COL9A1 causes autosomal recessive Stickler syndrome (type IV) with sensorineural hearing loss, myopia, vitreoretinopathy, and epiphyseal dysplasia; heterozygous carriers are unaffected, establishing COL9A1 as a recessive Stickler syndrome gene distinct from the dominant COL2A1/COL11A1/COL11A2 causes.","method":"Clinical evaluation, mutation analysis of COL9A1 coding region by sequencing in a consanguineous family, segregation analysis","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mutation identified and segregation confirmed in multiple affected and carrier family members, single lab","pmids":["16909383"],"is_preprint":false},{"year":2025,"finding":"In gastric cancer, COL9A1 secreted by ACTA2+ cancer-associated fibroblasts (CAFs) engages SDC4 (syndecan-4) on metastasis-initiating cells to maintain their identity and directly drives migratory and invasive phenotypes, establishing COL9A1-SDC4 as a ligand-receptor signaling axis between CAFs and cancer cells.","method":"Single-cell and spatial transcriptomics, computational cell-cell communication analysis, in vitro co-culture assays, genetic perturbation (knockdown/knockout)","journal":"Journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional validation by genetic perturbation and co-culture confirmed ligand-receptor axis, single study","pmids":["41999506"],"is_preprint":false},{"year":2025,"finding":"In colorectal cancer, KMT2D promotes COL9A1 expression by mediating H3K4me1 histone modification at the COL9A1 enhancer and recruiting the transcription factor ZNF460; COL9A1 knockdown attenuates cancer stem cell (CCSC) stemness and self-renewal, reduces ECM stiffness, hampers tumor growth in AOM/DSS and xenograft mouse models, and improves the tumor microenvironment.","method":"ChIP for H3K4me1 at COL9A1 enhancer, KMT2D/ZNF460 knockdown, COL9A1 knockdown/overexpression, polyacrylamide gel stiffness assays, in vivo mouse tumor models (AOM/DSS, xenograft)","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP plus in vivo genetic rescue experiments, multiple orthogonal methods, single lab","pmids":["40591048"],"is_preprint":false},{"year":1998,"finding":"The human COL9A1 gene spans ~90 kb and consists of 38 exons; the alternative exon 1* located in intron 6 is separated from exon 7 by a short intron (conserved across chick, human, mouse, and rat), explaining why transcripts from exon 1* are spliced directly to exon 8, generating the short isoform.","method":"Complete gene sequencing, exon-intron structure determination, promoter sequence analysis, comparative genomics","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — complete structural characterization of the gene with splice-site mapping, single study","pmids":["9707347"],"is_preprint":false}],"current_model":"COL9A1 encodes the α1 chain of the heterotrimeric FACIT collagen type IX; via alternative transcription from an intronic promoter it produces a short isoform expressed exclusively in bone (osteoblasts), while the long isoform predominates in cartilage and the tectorial membrane of the cochlea. SOX9 activates COL9A1 transcription through a novel enhancer mechanism requiring two cooperating SOX9 dimers at four binding sites, while the histone demethylase LSD1 represses COL9A1 by interacting with SOX9 and binding the promoter. In the extracellular matrix, short collagen IX in mineralized bone suppresses osteoclastic resorption through a non-cell-autonomous mechanism involving bone surface nanotopography and osteoblast RANKL/OPG ratio; in cancer contexts, COL9A1 signals through the SDC4 receptor on cancer cells to promote invasion and cancer stem cell identity, and its expression at the COL9A1 enhancer is epigenetically activated by KMT2D-mediated H3K4me1 and ZNF460 recruitment."},"narrative":{"mechanistic_narrative":"COL9A1 encodes the α1 chain of collagen type IX, an extracellular matrix collagen whose expression is governed by tissue-specific transcription and dual isoform output: the human gene spans ~90 kb across 38 exons and uses an alternative exon 1* located in intron 6, splicing directly to exon 8 to generate a short isoform [PMID:9707347], which is the exclusive isoform expressed by osteoblasts in bone [PMID:10595929]. Transcriptional control centers on SOX9, which activates a COL9A1 enhancer through a cooperative mechanism requiring two SOX9 dimers bound at two pairs of consensus sites [PMID:17264118]; this output is repressed by the histone demethylase LSD1, which interacts with SOX9 and is recruited to the COL9A1 promoter [PMID:32878268]. In skeletal tissue, collagen IX is deposited in mineralized bone matrix where it restrains osteoclastic resorption through a non-cell-autonomous mechanism involving bone surface nanotopography and the osteoblast RANKL/osteoprotegerin ratio, with collagen IX deficiency causing trabecular bone loss and abnormal bone healing [PMID:10595929, PMID:18251701]. The α1(IX) chain also localizes to the tectorial membrane and spiral ligament fibrocytes of the cochlea [PMID:18448257]. Loss-of-function and missense mutations in COL9A1 cause autosomal dominant multiple epiphyseal dysplasia [PMID:11565064] and autosomal recessive Stickler syndrome with sensorineural hearing loss, myopia, and vitreoretinopathy [PMID:16909383]. In cancer, COL9A1 acts as a secreted ligand: produced by cancer-associated fibroblasts, it engages the receptor SDC4 on cancer cells to drive invasion and maintain metastasis-initiating cell identity [PMID:41999506], and its enhancer is epigenetically activated by KMT2D-mediated H3K4me1 and ZNF460 recruitment to sustain cancer stem cell stemness and ECM stiffness [PMID:40591048].","teleology":[{"year":1998,"claim":"Resolving how a single gene yields a bone-specific short collagen IX, the gene's exon-intron architecture revealed an alternative first exon within an intron that explains the divergent transcript.","evidence":"Complete gene sequencing and exon-intron/splice-site mapping with comparative genomics across species","pmids":["9707347"],"confidence":"Medium","gaps":["Does not establish what regulates choice between the long and short promoters","No functional comparison of the two protein isoforms"]},{"year":1999,"claim":"It was unknown which COL9A1 isoform operates in bone; isoform-specific analysis showed the short isoform is exclusively expressed by osteoblasts and is required for normal bone restoration.","evidence":"Isoform-specific PCR, immunolocalization, and Col9a1-null mouse histology of healing alveolar bone","pmids":["10595929"],"confidence":"High","gaps":["Molecular mechanism by which short collagen IX supports bone remodeling not defined","Relationship to type X collagen abnormalities not mechanistically resolved"]},{"year":2001,"claim":"Establishing COL9A1 as a disease gene, a mutation was shown to cause autosomal dominant multiple epiphyseal dysplasia, expanding locus heterogeneity for the condition.","evidence":"Mutation screening by SSCP/sequencing and linkage analysis in MED probands","pmids":["11565064"],"confidence":"Medium","gaps":["No functional reconstitution of the mutation's effect on collagen IX assembly","Single family limits genotype-phenotype generalization"]},{"year":2006,"claim":"Distinguishing recessive from dominant collagenopathies, a homozygous nonsense mutation defined COL9A1 as a recessive Stickler syndrome gene spanning ocular, auditory and skeletal phenotypes.","evidence":"Clinical evaluation, COL9A1 sequencing and segregation analysis in a consanguineous family","pmids":["16909383"],"confidence":"Medium","gaps":["Tissue-level mechanism linking loss of function to hearing loss and vitreoretinopathy not shown","No protein-level characterization of the truncated chain"]},{"year":2007,"claim":"The transcriptional logic activating COL9A1 was undefined; mutagenesis revealed an enhancer requiring two cooperating SOX9 dimers at four sites, defining a combinatorial activation mechanism.","evidence":"Enhancer reporter assays in chondrocytic and 10T1/2 cells with site-directed mutagenesis of all four SOX9 sites and spacing mutants","pmids":["17264118"],"confidence":"High","gaps":["Whether the two SOX9 dimers contact directly or through a bridging factor not resolved","Cofactors completing the activation complex not identified"]},{"year":2008,"claim":"How bone matrix collagen IX influences resorption was unknown; null and heterozygous mice showed it limits osteoclast activity non-cell-autonomously via bone nanotopography and osteoblast RANKL/OPG balance.","evidence":"microCT, non-decalcified histology, serum resorption markers, and osteoclast cultures on mutant vs wild-type bone surfaces","pmids":["18251701"],"confidence":"High","gaps":["Direct receptor or signaling pathway mediating the topographic effect not identified","How collagen IX loss raises osteoblast RANKL/OPG ratio not mechanistically explained"]},{"year":2008,"claim":"To connect COL9A1 to its auditory phenotype, ultrastructural mapping placed collagen IX in the tectorial membrane and spiral ligament fibrocytes of the cochlea.","evidence":"Immunogold electron microscopy and confocal immunocytochemistry on rodent cochlear sections","pmids":["18448257"],"confidence":"Medium","gaps":["Single localization method without functional perturbation","Role of collagen IX in tectorial membrane mechanics not tested"]},{"year":2017,"claim":"Upstream inducers of COL9A1 in chondrocytes were unclear; an ATRA-driven cascade through RARα/CRABP2 and a sequential BMP2-WNT4-RUNX1 axis was mapped as inducing COL9A1.","evidence":"siRNA knockdown/overexpression epistasis and pharmacological agonist/antagonist treatments in antler chondrocytes","pmids":["28643469"],"confidence":"Medium","gaps":["Established in antler chondrocytes; conservation in mammalian cartilage not shown","Whether RUNX1 acts at the SOX9 enhancer not determined"]},{"year":2020,"claim":"The repressive arm of COL9A1 regulation was unknown; LSD1 was shown to interact with SOX9 and bind the COL9A1 promoter to repress expression, linking the gene to osteoarthritis-associated IL-1β signaling.","evidence":"RNA-seq after LSD1 loss, reciprocal Co-IP of LSD1 with SOX9, ChIP at COL9A1 promoter, and siRNA rescue in IL-1β-treated OA chondrocytes","pmids":["32878268"],"confidence":"High","gaps":["Whether LSD1's demethylase activity or scaffolding role drives repression not separated","Direct chromatin targets at the locus not fully mapped"]},{"year":2025,"claim":"A non-matrix signaling role emerged: COL9A1 secreted by cancer-associated fibroblasts engages SDC4 on cancer cells, defining a ligand-receptor axis sustaining metastasis-initiating cell identity and invasion.","evidence":"Single-cell and spatial transcriptomics, cell-cell communication analysis, co-culture, and genetic perturbation in gastric cancer","pmids":["41999506"],"confidence":"Medium","gaps":["Downstream SDC4 signaling effectors not defined","Single study without independent confirmation of the axis"]},{"year":2025,"claim":"How COL9A1 is switched on in cancer was addressed by showing KMT2D deposits H3K4me1 at the COL9A1 enhancer and recruits ZNF460, with COL9A1 driving cancer stem cell stemness and ECM stiffness.","evidence":"ChIP for H3K4me1, KMT2D/ZNF460 and COL9A1 perturbation, gel stiffness assays, and AOM/DSS and xenograft mouse models","pmids":["40591048"],"confidence":"Medium","gaps":["Relationship between this enhancer and the chondrocyte SOX9 enhancer not addressed","Mechanism linking COL9A1 to ECM stiffness not molecularly defined"]},{"year":null,"claim":"How the long versus short COL9A1 isoforms differ functionally, and how the chondrocyte SOX9/LSD1 regulatory module relates to the cancer KMT2D/ZNF460 enhancer activation, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of collagen IX assembly incorporating the α1 chain in the corpus","Direct downstream signaling from SDC4 engagement uncharacterized","Unification of the two enhancer-control mechanisms across tissues not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[3,4]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[8]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[3,4]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[3,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,7]}],"complexes":[],"partners":["SDC4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P20849","full_name":"Collagen alpha-1(IX) chain","aliases":[],"length_aa":921,"mass_kda":91.9,"function":"Structural component of hyaline cartilage and vitreous of the eye","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P20849/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/COL9A1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COL9A1","total_profiled":1310},"omim":[{"mim_id":"620022","title":"STICKLER SYNDROME, TYPE VI; STL6","url":"https://www.omim.org/entry/620022"},{"mim_id":"614135","title":"EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6","url":"https://www.omim.org/entry/614135"},{"mim_id":"614134","title":"STICKLER SYNDROME, TYPE IV; STL4","url":"https://www.omim.org/entry/614134"},{"mim_id":"613544","title":"CHROMOSOME 6q11-q14 DELETION SYNDROME","url":"https://www.omim.org/entry/613544"},{"mim_id":"608805","title":"AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 1; ANFH1","url":"https://www.omim.org/entry/608805"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":10.4},{"tissue":"choroid plexus","ntpm":23.9},{"tissue":"prostate","ntpm":10.8}],"url":"https://www.proteinatlas.org/search/COL9A1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P20849","domains":[{"cath_id":"2.60.120.200","chopping":"57-250","consensus_level":"high","plddt":94.8258,"start":57,"end":250}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P20849","model_url":"https://alphafold.ebi.ac.uk/files/AF-P20849-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P20849-F1-predicted_aligned_error_v6.png","plddt_mean":61.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COL9A1","jax_strain_url":"https://www.jax.org/strain/search?query=COL9A1"},"sequence":{"accession":"P20849","fasta_url":"https://rest.uniprot.org/uniprotkb/P20849.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P20849/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P20849"}},"corpus_meta":[{"pmid":"11565064","id":"PMC_11565064","title":"A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11565064","citation_count":142,"is_preprint":false},{"pmid":"16909383","id":"PMC_16909383","title":"A new autosomal recessive form of Stickler syndrome is caused by a mutation in the COL9A1 gene.","date":"2006","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16909383","citation_count":124,"is_preprint":false},{"pmid":"10788539","id":"PMC_10788539","title":"Linkage analysis of candidate genes as susceptibility loci for osteoarthritis-suggestive linkage of COL9A1 to female hip osteoarthritis.","date":"2000","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10788539","citation_count":65,"is_preprint":false},{"pmid":"1639419","id":"PMC_1639419","title":"Synteny between the loci for a novel FACIT-like collagen locus (D6S228E) and alpha 1 (IX) collagen (COL9A1) on 6q12-q14 in humans.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1639419","citation_count":45,"is_preprint":false},{"pmid":"21421862","id":"PMC_21421862","title":"Autosomal recessive Stickler syndrome in two families is caused by mutations in the COL9A1 gene.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21421862","citation_count":42,"is_preprint":false},{"pmid":"17264118","id":"PMC_17264118","title":"A Col9a1 enhancer element activated by two interdependent SOX9 dimers.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17264118","citation_count":42,"is_preprint":false},{"pmid":"9707347","id":"PMC_9707347","title":"Human COL9A1 and COL9A2 genes. Two genes of 90 and 15 kb code for similar polypeptides of the same collagen molecule.","date":"1998","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9707347","citation_count":41,"is_preprint":false},{"pmid":"31090205","id":"PMC_31090205","title":"Homozygous Type IX collagen variants (COL9A1, COL9A2, and COL9A3) causing recessive Stickler syndrome-Expanding the phenotype.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31090205","citation_count":39,"is_preprint":false},{"pmid":"9143499","id":"PMC_9143499","title":"Complete primary structure of two splice variants of collagen XII, and assignment of alpha 1(XII) collagen (COL12A1), alpha 1(IX) collagen (COL9A1), and alpha 1(XIX) collagen (COL19A1) to human chromosome 6q12-q13.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9143499","citation_count":37,"is_preprint":false},{"pmid":"8244386","id":"PMC_8244386","title":"Physical and linkage mapping of the human and murine genes for the alpha 1 chain of type IX collagen (COL9A1).","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8244386","citation_count":33,"is_preprint":false},{"pmid":"18251701","id":"PMC_18251701","title":"Trabecular bone deterioration in col9a1+/- mice associated with enlarged osteoclasts adhered to collagen IX-deficient bone.","date":"2008","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/18251701","citation_count":25,"is_preprint":false},{"pmid":"18448257","id":"PMC_18448257","title":"The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea.","date":"2008","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18448257","citation_count":24,"is_preprint":false},{"pmid":"15880806","id":"PMC_15880806","title":"Evidence for a role of the genomic region of the gene encoding for the alpha1 chain of type IX collagen (COL9A1) in hip osteoarthritis: A population-based study.","date":"2005","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/15880806","citation_count":19,"is_preprint":false},{"pmid":"25774918","id":"PMC_25774918","title":"COL9A1 gene polymorphism is associated with Kashin-Beck disease in a northwest Chinese Han population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25774918","citation_count":16,"is_preprint":false},{"pmid":"31732751","id":"PMC_31732751","title":"Relationship of COL9A1 and SOX9 Genes with Genetic Susceptibility of Postmenopausal Osteoporosis.","date":"2019","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/31732751","citation_count":15,"is_preprint":false},{"pmid":"16718610","id":"PMC_16718610","title":"Characterization of an abundant COL9A1 transcript in the cochlea with a novel 3' UTR: Expression studies and detection of miRNA target sequence.","date":"2006","source":"Journal of the Association for Research in Otolaryngology : JARO","url":"https://pubmed.ncbi.nlm.nih.gov/16718610","citation_count":13,"is_preprint":false},{"pmid":"32878268","id":"PMC_32878268","title":"The Lysine Specific Demethylase-1 Negatively Regulates the COL9A1 Gene in Human Articular Chondrocytes.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32878268","citation_count":12,"is_preprint":false},{"pmid":"10595929","id":"PMC_10595929","title":"A short isoform of Col9a1 supports alveolar bone repair.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10595929","citation_count":10,"is_preprint":false},{"pmid":"17548304","id":"PMC_17548304","title":"[Analysis of association between COL9A1 gene and idiopathic congenital talipes equinovarus].","date":"2007","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/17548304","citation_count":9,"is_preprint":false},{"pmid":"30657779","id":"PMC_30657779","title":"Variants in FAT1 and COL9A1 genes in male population with or without substance use to assess the risk factors for oral malignancy.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30657779","citation_count":8,"is_preprint":false},{"pmid":"28643469","id":"PMC_28643469","title":"ATRA Signaling Regulates the Expression of COL9A1 through BMP2-WNT4-RUNX1 Pathway in Antler Chondrocytes.","date":"2017","source":"Journal of experimental zoology. Part B, Molecular and developmental evolution","url":"https://pubmed.ncbi.nlm.nih.gov/28643469","citation_count":6,"is_preprint":false},{"pmid":"33973556","id":"PMC_33973556","title":"FAMILIAL EXUDATIVE VITREOTINOPATHY-LIKE FEATURES IN STICKLER TYPE IV ASSOCIATED WITH NOVEL VARIANTS IN COL9A1.","date":"2023","source":"Retinal cases & brief reports","url":"https://pubmed.ncbi.nlm.nih.gov/33973556","citation_count":6,"is_preprint":false},{"pmid":"21672422","id":"PMC_21672422","title":"[Expression of COL9A1 gene and its polymorphism in children with idiopathic congenital talipes equinovarus].","date":"2011","source":"Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/21672422","citation_count":5,"is_preprint":false},{"pmid":"33372835","id":"PMC_33372835","title":"Gene Environment Interactions Between the COL9A1 Gene and Maternal Drinking of Alcohol Contribute to the Risk of Congenital Talipes Equinovarus.","date":"2020","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/33372835","citation_count":4,"is_preprint":false},{"pmid":"36420106","id":"PMC_36420106","title":"Assessment of the COL9A1 Single Nucleotide Polymorphism with Severity of clubfoot in a paediatric population along with their biological mothers.","date":"2022","source":"Journal of clinical orthopaedics and trauma","url":"https://pubmed.ncbi.nlm.nih.gov/36420106","citation_count":3,"is_preprint":false},{"pmid":"31315069","id":"PMC_31315069","title":"Exome-wide copy number variation analysis identifies a COL9A1 in frame deletion that is associated with hearing loss.","date":"2019","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31315069","citation_count":2,"is_preprint":false},{"pmid":"38858754","id":"PMC_38858754","title":"A thorough analysis of data on the correlation between COL9A1 polymorphisms and the susceptibility to congenital talipes equinovarus: a meta-analysis.","date":"2024","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/38858754","citation_count":1,"is_preprint":false},{"pmid":"40591048","id":"PMC_40591048","title":"KMT2D/ZNF460-induced COL9A1-mediated extracellular matrix stiffness maintains the cancer stem cell pool to promote colorectal cancer progression.","date":"2025","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40591048","citation_count":0,"is_preprint":false},{"pmid":"39636322","id":"PMC_39636322","title":"COL9A1-related disorder with pectus carinatum, without epiphyseal dysplasia: case report and review of literature.","date":"2024","source":"Skeletal radiology","url":"https://pubmed.ncbi.nlm.nih.gov/39636322","citation_count":0,"is_preprint":false},{"pmid":"41999506","id":"PMC_41999506","title":"Formation of the pre-metastatic niche by COL9A1 + cancer-associated fibroblasts via SDC4 engagement promotes multi-organ metastasis in gastric cancer.","date":"2026","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/41999506","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.18.670791","title":"Aberrant epithelialization: A plausible factor for the development of endometrial polyps","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.670791","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.19.654577","title":"The maternal inflammatory proteome during pregnancy and its role in predicting the risk of spontaneous preterm birth","date":"2025-05-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.19.654577","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18364,"output_tokens":3189,"usd":0.051464,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10629,"output_tokens":3821,"usd":0.074335,"stage2_stop_reason":"end_turn"},"total_usd":0.125799,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"A COL9A1 enhancer element contains four SOX9 consensus binding sites arranged as two pairs of dimeric binding sites; mutation of any one of the four sites eliminates enhancer activity in chondrocytic cells, and increasing the spacing between the two pairs also eliminates activity, indicating that two SOX9 dimers must interact (directly or indirectly) when bound at the two pairs of sites to form a functional transcriptional activation complex.\",\n      \"method\": \"Enhancer reporter assays in chondrocytic cells and 10T1/2 cells, site-directed mutagenesis of individual SOX9 binding sites, SOX9 cotransfection/overexpression\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro/cell-based reconstitution with mutagenesis of all four sites plus spacing mutations, single lab but multiple orthogonal mutational approaches\",\n      \"pmids\": [\"17264118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LSD1 (Lysine-Specific Demethylase-1) negatively regulates COL9A1 in human articular chondrocytes: LSD1 physically interacts with the transcription factor SOX9 and is recruited to the COL9A1 promoter, repressing its expression; LSD1 depletion prevents IL-1β-induced decrease in COL9A1 in OA chondrocytes.\",\n      \"method\": \"RNA sequencing after LSD1 loss-of-function, co-immunoprecipitation of LSD1 with SOX9, chromatin immunoprecipitation (ChIP) at COL9A1 promoter, siRNA knockdown in OA chondrocytes with IL-1β treatment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, and functional rescue in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"32878268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A short transcriptional isoform of Col9a1 (generated by alternative transcription) is the exclusive isoform expressed in bone (osteoblasts/alveolar bone); Col9a1-null mutant mice show abnormal alveolar bone wound healing with absent or disorganized trabecular bone and abnormal type X collagen immunostaining in primary spongiosa, establishing that the short isoform supports bone restoration and remodeling.\",\n      \"method\": \"Sequence-specific PCR distinguishing long vs. short isoforms, immunolocalization of type IX collagen in healing bone, Col9a1-null mutant mouse analysis (histology, immunostaining for type X collagen)\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with specific skeletal phenotype plus isoform-specific PCR and immunolocalization, single lab with multiple methods\",\n      \"pmids\": [\"10595929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Short collagen IX (encoded by the col9a1 gene via alternative transcription) is expressed by osteoblasts and incorporated into mineralized bone matrix; col9a1 heterozygous and null mutant mice exhibit trabecular bone loss associated with enlarged, flattened osteoclasts that form large resorption pits on collagen IX-deficient bone surfaces lacking normal nanotopography; col9a1(+/-) osteoblasts show elevated RANKL/osteoprotegerin ratio, suggesting a non-cell-autonomous mechanism by which bone matrix collagen IX limits osteoclastic resorption.\",\n      \"method\": \"microCT and non-decalcified histology of col9a1-null and heterozygous mice, gene expression assays (PCR, microarray), TRACP-5b and CTX serum assays, in vitro osteoclast culture on mutant vs. wild-type calvaria, RAW264.7-derived osteoclast morphology assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO/heterozygote model with multiple orthogonal in vivo and in vitro readouts in single lab\",\n      \"pmids\": [\"18251701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Collagen type IX (including the COL9A1-encoded α1 chain) localizes within the tectorial membrane and in fibrocytes of the spiral ligament of the cochlea, as demonstrated by immunogold cytochemistry at the ultrastructural level.\",\n      \"method\": \"Confocal immunocytochemistry and postembedding immunogold electron microscopy on rat and mouse cochlear cryostat sections\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct ultrastructural localization in cochlea, single lab, single method\",\n      \"pmids\": [\"18448257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In antler chondrocytes, ATRA signaling induces COL9A1 expression via a BMP2-WNT4-RUNX1 pathway: RARα mediates the effect (RARα agonist Am80 induces COL9A1; RARα antagonist blocks it); CRABP2 is required for ATRA-induced COL9A1 upregulation; BMP2 and WNT4 act sequentially (WNT4 downstream of BMP2) to mediate ATRA's effect; RUNX1 acts downstream of BMP2 and WNT4 as a transcriptional intermediary to activate COL9A1.\",\n      \"method\": \"siRNA knockdown and overexpression of CRABP2, RARα, RXRα, BMP2, WNT4, RUNX1 in antler chondrocytes; pharmacological agonist/antagonist treatments; RT-PCR/Western blot for COL9A1\",\n      \"journal\": \"Journal of experimental zoology. Part B, Molecular and developmental evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — epistasis established by sequential knockdown/overexpression experiments, single lab, multiple pathway components tested\",\n      \"pmids\": [\"28643469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A mutation in COL9A1 (in the alpha1(IX) chain) can cause autosomal dominant multiple epiphyseal dysplasia (MED), establishing COL9A1 as a causative gene for MED and expanding locus heterogeneity for this condition.\",\n      \"method\": \"Mutation screening of COL9A1 coding region by SSCP/sequencing in MED probands; linkage analysis to exclude other known loci\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — disease-causing mutation identified by sequencing in a single family, no functional reconstitution\",\n      \"pmids\": [\"11565064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Homozygous loss-of-function mutation (R295X) in COL9A1 causes autosomal recessive Stickler syndrome (type IV) with sensorineural hearing loss, myopia, vitreoretinopathy, and epiphyseal dysplasia; heterozygous carriers are unaffected, establishing COL9A1 as a recessive Stickler syndrome gene distinct from the dominant COL2A1/COL11A1/COL11A2 causes.\",\n      \"method\": \"Clinical evaluation, mutation analysis of COL9A1 coding region by sequencing in a consanguineous family, segregation analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mutation identified and segregation confirmed in multiple affected and carrier family members, single lab\",\n      \"pmids\": [\"16909383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In gastric cancer, COL9A1 secreted by ACTA2+ cancer-associated fibroblasts (CAFs) engages SDC4 (syndecan-4) on metastasis-initiating cells to maintain their identity and directly drives migratory and invasive phenotypes, establishing COL9A1-SDC4 as a ligand-receptor signaling axis between CAFs and cancer cells.\",\n      \"method\": \"Single-cell and spatial transcriptomics, computational cell-cell communication analysis, in vitro co-culture assays, genetic perturbation (knockdown/knockout)\",\n      \"journal\": \"Journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional validation by genetic perturbation and co-culture confirmed ligand-receptor axis, single study\",\n      \"pmids\": [\"41999506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In colorectal cancer, KMT2D promotes COL9A1 expression by mediating H3K4me1 histone modification at the COL9A1 enhancer and recruiting the transcription factor ZNF460; COL9A1 knockdown attenuates cancer stem cell (CCSC) stemness and self-renewal, reduces ECM stiffness, hampers tumor growth in AOM/DSS and xenograft mouse models, and improves the tumor microenvironment.\",\n      \"method\": \"ChIP for H3K4me1 at COL9A1 enhancer, KMT2D/ZNF460 knockdown, COL9A1 knockdown/overexpression, polyacrylamide gel stiffness assays, in vivo mouse tumor models (AOM/DSS, xenograft)\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP plus in vivo genetic rescue experiments, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"40591048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The human COL9A1 gene spans ~90 kb and consists of 38 exons; the alternative exon 1* located in intron 6 is separated from exon 7 by a short intron (conserved across chick, human, mouse, and rat), explaining why transcripts from exon 1* are spliced directly to exon 8, generating the short isoform.\",\n      \"method\": \"Complete gene sequencing, exon-intron structure determination, promoter sequence analysis, comparative genomics\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — complete structural characterization of the gene with splice-site mapping, single study\",\n      \"pmids\": [\"9707347\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COL9A1 encodes the α1 chain of the heterotrimeric FACIT collagen type IX; via alternative transcription from an intronic promoter it produces a short isoform expressed exclusively in bone (osteoblasts), while the long isoform predominates in cartilage and the tectorial membrane of the cochlea. SOX9 activates COL9A1 transcription through a novel enhancer mechanism requiring two cooperating SOX9 dimers at four binding sites, while the histone demethylase LSD1 represses COL9A1 by interacting with SOX9 and binding the promoter. In the extracellular matrix, short collagen IX in mineralized bone suppresses osteoclastic resorption through a non-cell-autonomous mechanism involving bone surface nanotopography and osteoblast RANKL/OPG ratio; in cancer contexts, COL9A1 signals through the SDC4 receptor on cancer cells to promote invasion and cancer stem cell identity, and its expression at the COL9A1 enhancer is epigenetically activated by KMT2D-mediated H3K4me1 and ZNF460 recruitment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COL9A1 encodes the α1 chain of collagen type IX, an extracellular matrix collagen whose expression is governed by tissue-specific transcription and dual isoform output: the human gene spans ~90 kb across 38 exons and uses an alternative exon 1* located in intron 6, splicing directly to exon 8 to generate a short isoform [#10], which is the exclusive isoform expressed by osteoblasts in bone [#2]. Transcriptional control centers on SOX9, which activates a COL9A1 enhancer through a cooperative mechanism requiring two SOX9 dimers bound at two pairs of consensus sites [#0]; this output is repressed by the histone demethylase LSD1, which interacts with SOX9 and is recruited to the COL9A1 promoter [#1]. In skeletal tissue, collagen IX is deposited in mineralized bone matrix where it restrains osteoclastic resorption through a non-cell-autonomous mechanism involving bone surface nanotopography and the osteoblast RANKL/osteoprotegerin ratio, with collagen IX deficiency causing trabecular bone loss and abnormal bone healing [#2, #3]. The α1(IX) chain also localizes to the tectorial membrane and spiral ligament fibrocytes of the cochlea [#4]. Loss-of-function and missense mutations in COL9A1 cause autosomal dominant multiple epiphyseal dysplasia [#6] and autosomal recessive Stickler syndrome with sensorineural hearing loss, myopia, and vitreoretinopathy [#7]. In cancer, COL9A1 acts as a secreted ligand: produced by cancer-associated fibroblasts, it engages the receptor SDC4 on cancer cells to drive invasion and maintain metastasis-initiating cell identity [#8], and its enhancer is epigenetically activated by KMT2D-mediated H3K4me1 and ZNF460 recruitment to sustain cancer stem cell stemness and ECM stiffness [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolving how a single gene yields a bone-specific short collagen IX, the gene's exon-intron architecture revealed an alternative first exon within an intron that explains the divergent transcript.\",\n      \"evidence\": \"Complete gene sequencing and exon-intron/splice-site mapping with comparative genomics across species\",\n      \"pmids\": [\"9707347\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish what regulates choice between the long and short promoters\", \"No functional comparison of the two protein isoforms\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"It was unknown which COL9A1 isoform operates in bone; isoform-specific analysis showed the short isoform is exclusively expressed by osteoblasts and is required for normal bone restoration.\",\n      \"evidence\": \"Isoform-specific PCR, immunolocalization, and Col9a1-null mouse histology of healing alveolar bone\",\n      \"pmids\": [\"10595929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which short collagen IX supports bone remodeling not defined\", \"Relationship to type X collagen abnormalities not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing COL9A1 as a disease gene, a mutation was shown to cause autosomal dominant multiple epiphyseal dysplasia, expanding locus heterogeneity for the condition.\",\n      \"evidence\": \"Mutation screening by SSCP/sequencing and linkage analysis in MED probands\",\n      \"pmids\": [\"11565064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional reconstitution of the mutation's effect on collagen IX assembly\", \"Single family limits genotype-phenotype generalization\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Distinguishing recessive from dominant collagenopathies, a homozygous nonsense mutation defined COL9A1 as a recessive Stickler syndrome gene spanning ocular, auditory and skeletal phenotypes.\",\n      \"evidence\": \"Clinical evaluation, COL9A1 sequencing and segregation analysis in a consanguineous family\",\n      \"pmids\": [\"16909383\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-level mechanism linking loss of function to hearing loss and vitreoretinopathy not shown\", \"No protein-level characterization of the truncated chain\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The transcriptional logic activating COL9A1 was undefined; mutagenesis revealed an enhancer requiring two cooperating SOX9 dimers at four sites, defining a combinatorial activation mechanism.\",\n      \"evidence\": \"Enhancer reporter assays in chondrocytic and 10T1/2 cells with site-directed mutagenesis of all four SOX9 sites and spacing mutants\",\n      \"pmids\": [\"17264118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the two SOX9 dimers contact directly or through a bridging factor not resolved\", \"Cofactors completing the activation complex not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"How bone matrix collagen IX influences resorption was unknown; null and heterozygous mice showed it limits osteoclast activity non-cell-autonomously via bone nanotopography and osteoblast RANKL/OPG balance.\",\n      \"evidence\": \"microCT, non-decalcified histology, serum resorption markers, and osteoclast cultures on mutant vs wild-type bone surfaces\",\n      \"pmids\": [\"18251701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct receptor or signaling pathway mediating the topographic effect not identified\", \"How collagen IX loss raises osteoblast RANKL/OPG ratio not mechanistically explained\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"To connect COL9A1 to its auditory phenotype, ultrastructural mapping placed collagen IX in the tectorial membrane and spiral ligament fibrocytes of the cochlea.\",\n      \"evidence\": \"Immunogold electron microscopy and confocal immunocytochemistry on rodent cochlear sections\",\n      \"pmids\": [\"18448257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single localization method without functional perturbation\", \"Role of collagen IX in tectorial membrane mechanics not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Upstream inducers of COL9A1 in chondrocytes were unclear; an ATRA-driven cascade through RARα/CRABP2 and a sequential BMP2-WNT4-RUNX1 axis was mapped as inducing COL9A1.\",\n      \"evidence\": \"siRNA knockdown/overexpression epistasis and pharmacological agonist/antagonist treatments in antler chondrocytes\",\n      \"pmids\": [\"28643469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Established in antler chondrocytes; conservation in mammalian cartilage not shown\", \"Whether RUNX1 acts at the SOX9 enhancer not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The repressive arm of COL9A1 regulation was unknown; LSD1 was shown to interact with SOX9 and bind the COL9A1 promoter to repress expression, linking the gene to osteoarthritis-associated IL-1β signaling.\",\n      \"evidence\": \"RNA-seq after LSD1 loss, reciprocal Co-IP of LSD1 with SOX9, ChIP at COL9A1 promoter, and siRNA rescue in IL-1β-treated OA chondrocytes\",\n      \"pmids\": [\"32878268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LSD1's demethylase activity or scaffolding role drives repression not separated\", \"Direct chromatin targets at the locus not fully mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A non-matrix signaling role emerged: COL9A1 secreted by cancer-associated fibroblasts engages SDC4 on cancer cells, defining a ligand-receptor axis sustaining metastasis-initiating cell identity and invasion.\",\n      \"evidence\": \"Single-cell and spatial transcriptomics, cell-cell communication analysis, co-culture, and genetic perturbation in gastric cancer\",\n      \"pmids\": [\"41999506\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream SDC4 signaling effectors not defined\", \"Single study without independent confirmation of the axis\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"How COL9A1 is switched on in cancer was addressed by showing KMT2D deposits H3K4me1 at the COL9A1 enhancer and recruits ZNF460, with COL9A1 driving cancer stem cell stemness and ECM stiffness.\",\n      \"evidence\": \"ChIP for H3K4me1, KMT2D/ZNF460 and COL9A1 perturbation, gel stiffness assays, and AOM/DSS and xenograft mouse models\",\n      \"pmids\": [\"40591048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between this enhancer and the chondrocyte SOX9 enhancer not addressed\", \"Mechanism linking COL9A1 to ECM stiffness not molecularly defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the long versus short COL9A1 isoforms differ functionally, and how the chondrocyte SOX9/LSD1 regulatory module relates to the cancer KMT2D/ZNF460 enhancer activation, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of collagen IX assembly incorporating the α1 chain in the corpus\", \"Direct downstream signaling from SDC4 engagement uncharacterized\", \"Unification of the two enhancer-control mechanisms across tissues not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SDC4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}